Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 2003

View Archived Issues

Novel agents for gastroesophageal reflux disease identified at AstraZeneca

Evidence of antitumor activity found for Xyotax in recurrent ovarian cancer

Elan and Pharmacia present novel beta-secretase inhibitors for AD and other disorders

Orally active analgesics with minimal stimulant effects discovered at Dainippon

Grelan researchers prepare and test new naphthyridine-based PDE4 inhibitors

Novel PPAR agonists identified by Eisai scientists

Fuji Yakuhin identifies new series of antitumor agents

Selective, small-molecule inhibitor of AKT kinase activity induces apoptosis in cancer cells

Texas Biotechnology to reacquire full sitaxsentan rights

Toray and Fujisawa to codevelop TRK-820 in Europe

New Bcl-2/Bcl-XL inhibitor may facilitate chemotherapy in resistant ovarian cancer

GenoMed evaluates intravenous drug regimen for acute kidney failure

Sunesis awarded SBIR grant for novel kinase inhibitor drug discovery

Recent accomplishments at Icos

Docetaxel followed by NS-398 results in additive apoptotic effect in ovarian cancer cells

ATN-161 enters the clinic

Corixa and GSK form cancer vaccine collaboration

Phase IIb trial of eculizumab in rheumatoid arthritis completes enrollment

Catholic University of Louvain to terminate agreement with BioTransplant

French researchers identify potent and selective 5-HT4 antagonist/partial agonist

BioSante signs malaria vaccine CRADA with U.S. Navy

Ivax to develop immunotoxin to treat HIV

New Japanese pharmaceutical company begins operations

FDA accepts memantine filing

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...